Atherosclerosis (hardening of the arteries) occurs with aging. The treatment for atherosclerosis often results in the arteries reblocking (restenosis). While techniques such as balloon angioplasty exist to remove atherosclerotic lesions, 1-9% of patients experience immediate occlusive complications, and up to 60% of patients experience restenosis within six months.

Researchers at the Australian Institute for Bioengineering and Nanotechnology have discovered a potential preventative treatment which localises existing anti-restenotic drugs at the site of surgery for longer, overcoming the need for a stent.

• Investment
• Commercial partners for preclinical and clinical development